Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Kath Kerry

- PMLiVE

New evidence review uncovers ‘significant’ link between particulate matter and dementia

Information from 17 existing studies was reviewed, involving 91 million people

- PMLiVE

Eli Lilly and Purdue sign $92.5m deal for pharma manufacturing scholarships

Participating students with be able to compete for a role at the company following graduation

Achieving health equity: a focused approach to redefining our medical communications efforts

By the HCG Health Disparities and Inequities Council

Expanding Opportunities for Healthcare with “Digital Twins”

Brad Womble, Senior Director of Strategy, Marketing and Mergers & Acquisitions, at Jabil Healthcare dives into several thought-provoking topics, including how insights from “digital twins” can be used to improve...

Impetus Digital

A female clinical using her smartphone wearing blue scrubs

Overcoming challenges in digital pharma to get to launch quicker

We take a look at why it can take pharma businesses so long to get their digital products into the hands of patients or HCPs, and what can be done...

Graphite Digital

- PMLiVE

Sight-saving MedTech sleep mask could save the NHS multimillions

MedTech company PolyPhotonix has had its innovative diabetes sleep mask adopted in the NHS for the first time

Onyx Health

- PMLiVE

The health paradigm shift

By Maxine Smith and Alexandra Fulford

- PMLiVE

Innovative Trials on the latest ABPI report

Kate Shaw, Innovative Trials Founder & CEO, commented on the latest ABPI report

Innovative Trials

Create Health's latest recruits gathered in the agency's Bristol studio

Healthcare marketing agency Create Health continues to grow

Eight new recruits, including Business Development Director, Marketing Manager and Medical Writer join Create Health.

Create Health

- PMLiVE

WHO publishes first-ever fungal priority pathogens list in face of antimicrobial resistance

The list highlights the public health threat presented by fungal infections on a global scale

- PMLiVE

Janssen’s Tecvayli granted FDA approval for multiple myeloma

A phase 2 study demonstrated an overall response rate of 61.8% in Tecvayli-treated patients

- PMLiVE

Alexion’s Ultomiris shows promise in neuromyelitis optica spectrum disorder phase 3 trial

Ultomiris-treated patients showed zero relapses with a median treatment duration of 73 weeks

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links